Mkts

Lexaria Bioscience Corp.

NASDAQ: LEXX
$3.49-0.28 (-7.43%)
As of Oct 30, 4:00 PM ET

Key statistics

Day range
3.093.63
52-week range
2.4321.60
Today
Open3.63
Previous close3.49
Volume—
Valuation
Market cap7.35M
P/E ratio—
EPS (TTM)-3.35
Income & risk
Dividend / yield—
Beta0.61
Avg volume55.9K
Discussion

LEXX News

Stories mentioning LEXX from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Feb 28Q4 '25Nov 30Q3 '25Aug 31Q2 '25May 31Q1 '25Feb 28Q4 '24Nov 30Q3 '24Aug 31Q2 '24May 31
Income Statement
Revenue20.000.00174.00174.00174.00184.0084.0084.00
Cost of Goods Sold0.000.000.000.000.003.000.000.00
Gross Profit20.000.00174.00174.00174.00181.0084.0084.00
Operating Expenses
Research & Development475.00671.001,8822,7181,6861,953968.00573.00
Sales General & Admin
Total Operating Expenses1,4721,5742,8633,9242,9252,8722,2871,827
Operating Income (Loss)(1,452)(1,574)(2,689)(3,750)(2,751)(2,691)(2,203)(1,743)
Interest Income
Interest Expense
Other Expense(16.00)16.00(41.00)
Pretax Income
Tax Provision3.002.000.000.00
Net Income (Loss)(1,450)(1,595)(2,696)(3,789)(2,713)(2,704)(2,184)(1,782)
Earnings Per Share (Basic)
Earnings Per Share (Diluted)(0.06)(0.07)(0.15)(0.21)(0.15)(0.16)(0.18)(0.13)
Weighted Average Shares Outstanding (Basic)
Weighted Average Shares Outstanding (Diluted)24,44421,37617,99918,29817,51216,66912,38413,855

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About LEXX

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a stock listed on the Nasdaq Stock Market under the ticker symbol LEXX. It last traded at $3.49 (Oct 30, 2026, 4:00 PM ET), down 7.4% on the day. That gives Lexaria Bioscience a market capitalisation of $7.4M.

Over the past 52 weeks LEXX has traded between $2.43 and $21.60.

Revenue for the quarter ended Feb 28, 2026 was $20.0K; a net loss of $1.5M. Revenue was down 88.5% from $174.0K in the quarter ended Feb 28, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Feb 28, 2026$20.0K-$1.5M-7250.0%
Nov 30, 2025$0-$1.6M—
Aug 31, 2025$174.0K-$2.7M-1549.4%
May 31, 2025$174.0K-$3.8M-2177.6%

From Lexaria Bioscience’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…